FDA APPROVED
IMPORTANT SAFETY INFORMATION
OMIDRIA
™
must be diluted prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any
of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities
to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal
anti-inflammatories (NSAIDs), or have a past medical history of asthma.
The most common reported ocular adverse reactions at 2-24% are eye irritation,
posterior capsule opacification, increased intraocular pressure, and anterior
chamber inflammation.
Use of OMIDRIA in children has not been established.
Please see full prescribing information for OMIDRIA
at www.omidria.com/prescribinginformation.
You are encouraged to report negative side
effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Omeros
®
and the Omeros logo
®
are registered trademarks, and
Omidria
™
and the Omidria logo
™
are trademarks, of Omeros Corporation.
© Omeros Corporation 2014, all rights reserved. 2014-067
IS THE TIME TO REDUCE POSTOPERATIVE OCULAR PAIN
